Syntr Health Technologies Announces An Oversubscribed $2.2 Million Seed Round To Accelerate Market Penetration Of Fda-Cleared Syntrfuge System
Amount Raised
$2.2 Million
Round Type
seed
Description
Syntr Health Technologies, Inc., a medical device company specializing in the processing of autologous adipose tissue, today announced a $2.2 million seed funding round, which includes previous investors, angels and surgeons participating in the round. Proceeds will be used to build out sales for its patented, FDA-cleared SyntrFuge SystemTM, a single-use disposable medical device that uses a patient's own adipose tissue (also known as fat tissue) at the point of care. The implantation of adipose tissue is known to aid in the natural rejuvenation of soft tissue in plastic and reconstructive surgery. Its minimally invasive approach processes the tissue in minutes resulting in a quick and efficient procedure.